Hyper IgM syndrome

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Vaccine 1 substance
Phase I (First in Human): 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase I (First in Human)

1 trial
  • Fondazione Telethon Ets Commercial
    AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD4 T-CELLS CRISPR-EDITED AT THE CD40LG LOCUS; PERTUSSIS FILAMENTOUS HAEMAGGLUTININ ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, TETANUS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, HAEMOPHILUS TYPE B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID ADSORBED ON ALUMINIUM PHOSPHATE, HEPATITIS B SURFACE ANTIGEN (RDNA) ADSORBED ON ALUMINIUM PHOSPHATE [PRODUCED IN S. CEREVISAE CELLS BY RDNA], DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) PRODUCED ON VERO CELLS; RABIES VIRUS (INACTIVATED) STRAIN FLURY LEP; TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN
    2025-524635-39-00 1 country n=4 Orphan
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Fondazione Telethon Ets Commercial 1 Phase I (First in Human) 0
← All indication landscapes